Skip to main content

Health Canada Endorses Lophophora Williamsii, Elevating Lophos Holdings Inc. as a Leader in Natural Health Innovation

Written by Customer Service on . Posted in Public Companies.

NAPANEE, Ontario, Jan. 23, 2024 (GLOBE NEWSWIRE) — Lophos Holdings Inc. (“Lophos”) (CSE:MESC), a trailblazer in the production of Lophophora williamsii (peyote), proudly announces a significant stride in the natural health sector. Health Canada’s recent recognition of Lophophora williamsii as a Natural Health Product ingredient marks a pivotal moment in the therapeutic use of psychoactive plants, reinforcing Lophos’ position at the forefront of this innovative field.

Groundbreaking Achievement

Lophos Pharmaceuticals Corp., a wholly owned subsidiary of Lophos Holdings Inc., operates from Napanee, Ontario, focusing on the cultivation and production of Lophophora williamsii. This decision by Health Canada not only highlights the therapeutic potential of Lophophora williamsii but also demonstrates Lophos’ commitment to integrating traditional wisdom with modern science to revolutionize natural health products.

CEO’s Vision

Claire Stawnyczy, CEO of Lophos, shared her excitement, stating, “Health Canada’s recognition is a validation of our commitment and a significant achievement for the industry. It opens avenues for novel and innovative applications of psychoactive cacti in promoting human well-being.” She added, “Being at the forefront of Lophophora williamsii cultivation, we are eager to provide our ethically cultivated cacti to drive innovation in natural health products.”

The Future Landscape

Health Canada’s decision marks a shift in the perception of psychoactive plants, blending traditional knowledge with cutting-edge science. Lophos stands at the intersection of this evolution, poised to unlock the full potential of Lophophora williamsii.

Strategic Highlights

  • Health Canada Recognition: The therapeutic promise of Lophophora williamsii is validated with this approval and listing in the Natural Health Product Ingredient.
  • Controlled Substance Dealers License: Ensures responsible cultivation and production at Lophos’ Napanee facility.
  • Innovation in Natural Health: Lophos leads the way in cultivating sustainable and effective natural health solutions.


Lophos Facility Highlights:

  • CSDL licensed facility.
  • Authorized to produce mescaline, psilocin, and psilocybin.
  • Authorized for the sale, transportation, and distribution of controlled substances including mescaline, psilocin, and psilocybin, DMT, LSD, MDMA, and ketamine.
  • Privately owned, state-of-the-art facility spanning 10,000 sq. ft., with 4,000 sq. ft. of dedicated cultivation space.


About Lophos

Lophos Pharmaceuticals Corp., a key subsidiary of Lophos Holdings Inc., is at the forefront of peyote cactus cultivation, research, and sale. Trading under the ticker “MESC” on the Canadian Securities Exchange (CSE), Lophos is committed to the ethical exploration and distribution of peyote, mescaline, psilocin, and psilocybin, as well as contributing to the evolving field of natural health products.

For further inquiries:

Contact: Giselle Barona, Lophos Holdings Inc.
Email: invest@lophos.com
Website: www.lophos.com
Phone: 1-833-450-7407

Cautionary Statement

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Lophos’ current belief or assumptions as to the outcome and timing of such future events. Forward-looking information in this press release includes information with respect to the Company’s peyote cactus product development. Forward-looking information is based on reasonable assumptions that have been made by Lophos at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Lophos is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Lophos’ final long form prospectus dated August 11, 2023, which is available on Lophos’s profile at www.sedarplus.ca.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.